PAS
PLX icon

Point72 Asia (Singapore)’s Protalix BioTherapeutics PLX Stock Holding History

Point72 Asia (Singapore)’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-54,174
Closed -$139K – 1181
2025
Q1 		$139K Buy
54,174
+667
+1% +$1.59K 0.04% 342
2024
Q4 		$101K Buy
53,507
+6,434
+14% +$9.1K 0.03% 368
2024
Q3 		$48K Sell
47,073
-21,090
-31% -$22.2K 0.01% 700
2024
Q2 		$79.8K Buy
+68,163
New +$80.5K 0.02% 541

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Point72 Asia (Singapore)'s PLX Position: Q2 2025 in Review

Point72 Asia (Singapore) sold out of Protalix BioTherapeutics (PLX) in Q2 2025, closing a stake of 54,174 shares — an estimated $139K sold.

Point72 Asia (Singapore) first reported a position in PLX in Q2 2024 and held it in 4 quarters. The position peaked at $139K in Q1 2025. 63 funds tracked by Wall St. Rank hold PLX as of Q2 2025.

  • Point72 Asia (Singapore) reported no remaining Protalix BioTherapeutics position as of Q2 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 54,174 Protalix BioTherapeutics shares in Q2 2025, an estimated $139K.
  • Point72 Asia (Singapore) first reported a position in Protalix BioTherapeutics in Q2 2024 and held it in 4 quarters.
  • Point72 Asia (Singapore)'s Protalix BioTherapeutics position peaked at $139K in Q1 2025.
  • 63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q2 2025, filed 14 Aug 2025.